Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 39 entries
Sorted by: Best Match Show Resources per page
Nutritional Status Impairment Due to Neoadjuvant Chemotherapy Predicts Post-Radical Cystectomy Complications.

Nutrients

Cohen S, Gal J, Freifeld Y, Khoury S, Dekel Y, Hofman A, Malshi K, Amiel G, Sagi I, Leibovici I, Golan S, Baniel J, Rozenzweig B, Dotan Z, Haifler M.
PMID: 34960023
Nutrients. 2021 Dec 14;13(12). doi: 10.3390/nu13124471.

BACKGROUND: Radical cystectomy (RC) is the standard treatment for muscle invasive bladder cancer (MIBC). Neoadjuvant chemotherapy (NAC) is associated with improved patient survival. The impact of NAC on nutritional status is understudied, while the association between malnutrition and poor...

Cite
Cohen S, Gal J, Freifeld Y, et al. Nutritional Status Impairment Due to Neoadjuvant Chemotherapy Predicts Post-Radical Cystectomy Complications. Nutrients. 2021;13(12)doi: 10.3390/nu13124471.
Cohen, S., Gal, J., Freifeld, Y., Khoury, S., Dekel, Y., Hofman, A., Malshi, K., Amiel, G., Sagi, I., Leibovici, I., Golan, S., Baniel, J., Rozenzweig, B., Dotan, Z., & Haifler, M. (2021). Nutritional Status Impairment Due to Neoadjuvant Chemotherapy Predicts Post-Radical Cystectomy Complications. Nutrients, 13(12), . https://doi.org/10.3390/nu13124471
Cohen, Sharon, et al. "Nutritional Status Impairment Due to Neoadjuvant Chemotherapy Predicts Post-Radical Cystectomy Complications." Nutrients vol. 13,12 (2021). doi: https://doi.org/10.3390/nu13124471
Cohen S, Gal J, Freifeld Y, Khoury S, Dekel Y, Hofman A, Malshi K, Amiel G, Sagi I, Leibovici I, Golan S, Baniel J, Rozenzweig B, Dotan Z, Haifler M. Nutritional Status Impairment Due to Neoadjuvant Chemotherapy Predicts Post-Radical Cystectomy Complications. Nutrients. 2021 Dec 14;13(12). doi: 10.3390/nu13124471. PMID: 34960023; PMCID: PMC8708207.
Copy Download .nbib Format: NLM
CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma.

JCI insight

Lewinsky H, Gunes EG, David K, Radomir L, Kramer MP, Pellegrino B, Perpinial M, Chen J, He TF, Mansour AG, Teng KY, Bhattacharya S, Caserta E, Troadec E, Lee P, Feng M, Keats J, Krishnan A, Rosenzweig M, Yu J, Caligiuri MA, Cohen Y, Shevetz O, Becker-Herman S, Pichiorri F, Rosen S, Shachar I.
PMID: 33465053
JCI Insight. 2021 Feb 22;6(4). doi: 10.1172/jci.insight.141683.

Multiple myeloma (MM) is characterized by an accumulation of malignant plasma cells (PCs) within the BM. The BM microenvironment supports survival of the malignant cells and is composed of cellular fractions that foster myeloma development and progression by suppression...

Cite
Lewinsky H, Gunes EG, David K, et al. CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma. JCI Insight. 2021;6(4)doi: 10.1172/jci.insight.141683.
Lewinsky, H., Gunes, E. G., David, K., Radomir, L., Kramer, M. P., Pellegrino, B., Perpinial, M., Chen, J., He, T. F., Mansour, A. G., Teng, K. Y., Bhattacharya, S., Caserta, E., Troadec, E., Lee, P., Feng, M., Keats, J., Krishnan, A., Rosenzweig, M., Yu, J., Caligiuri, M. A., Cohen, Y., Shevetz, O., Becker-Herman, S., Pichiorri, F., Rosen, S., & Shachar, I. (2021). CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma. JCI insight, 6(4), . https://doi.org/10.1172/jci.insight.141683
Lewinsky, Hadas, et al. "CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma." JCI insight vol. 6,4 (2021). doi: https://doi.org/10.1172/jci.insight.141683
Lewinsky H, Gunes EG, David K, Radomir L, Kramer MP, Pellegrino B, Perpinial M, Chen J, He TF, Mansour AG, Teng KY, Bhattacharya S, Caserta E, Troadec E, Lee P, Feng M, Keats J, Krishnan A, Rosenzweig M, Yu J, Caligiuri MA, Cohen Y, Shevetz O, Becker-Herman S, Pichiorri F, Rosen S, Shachar I. CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma. JCI Insight. 2021 Feb 22;6(4). doi: 10.1172/jci.insight.141683. PMID: 33465053; PMCID: PMC7934939.
Copy Download .nbib Format: NLM
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.

Leukemia

Krishnan A, Kapoor P, Palmer JM, Tsai NC, Kumar S, Lonial S, Htut M, Karanes C, Nathwani N, Rosenzweig M, Sahebi F, Somlo G, Duarte L, Sanchez JF, Auclair D, Forman SJ, Berdeja JG.
PMID: 32082000
Leukemia. 2018 Jul;32(7):1567-1574. doi: 10.1038/s41375-018-0038-8. Epub 2018 Feb 23.

In this phase I/II trial, a triplet regimen of ixazomib (Ixa: 3 or 4 mg), pomalidomide (Pom: 4 mg), and dexamethasone (Dex: 40 mg) was administered to 32 lenalidomide-refractory multiple myeloma (MM) patients; 31 were evaluable for response and...

Cite
Krishnan A, Kapoor P, Palmer JM, et al. Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia. 2018;32(7):1567-1574doi: 10.1038/s41375-018-0038-8.
Krishnan, A., Kapoor, P., Palmer, J. M., Tsai, N. C., Kumar, S., Lonial, S., Htut, M., Karanes, C., Nathwani, N., Rosenzweig, M., Sahebi, F., Somlo, G., Duarte, L., Sanchez, J. F., Auclair, D., Forman, S. J., & Berdeja, J. G. (2018). Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia, 32(7), 1567-1574. https://doi.org/10.1038/s41375-018-0038-8
Krishnan, Amrita, et al. "Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma." Leukemia vol. 32,7 (2018): 1567-1574. doi: https://doi.org/10.1038/s41375-018-0038-8
Krishnan A, Kapoor P, Palmer JM, Tsai NC, Kumar S, Lonial S, Htut M, Karanes C, Nathwani N, Rosenzweig M, Sahebi F, Somlo G, Duarte L, Sanchez JF, Auclair D, Forman SJ, Berdeja JG. Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia. 2018 Jul;32(7):1567-1574. doi: 10.1038/s41375-018-0038-8. Epub 2018 Feb 23. PMID: 32082000; PMCID: PMC6005710.
Copy Download .nbib Format: NLM
[ Retention : a challenging problem. An interview with Simon J. Littlewood].

L' Orthodontie francaise

Littlewood SJ, Rozencweig S.
PMID: 33146612
Orthod Fr. 2020 Oct 01;91(3):173-178. doi: 10.1684/orthodfr.2020.18.

No abstract available.

Cite
Littlewood SJ, Rozencweig S. La contention : un véritable défi Entretien avec Simon J. Littlewood. [ Retention : a challenging problem. An interview with Simon J. Littlewood]. Orthod Fr. 2020;91(3):173-178doi: 10.1684/orthodfr.2020.18.
Littlewood, S. J., & Rozencweig, S. (2020). La contention : un véritable défi Entretien avec Simon J. Littlewood. [ Retention : a challenging problem. An interview with Simon J. Littlewood]. L' Orthodontie francaise, 91(3), 173-178. https://doi.org/10.1684/orthodfr.2020.18
Littlewood, Simon J, and Rozencweig, Sophie. "La contention : un véritable défi Entretien avec Simon J. Littlewood." [ Retention : a challenging problem. An interview with Simon J. Littlewood]. L' Orthodontie francaise vol. 91,3 (2020): 173-178. doi: https://doi.org/10.1684/orthodfr.2020.18
Littlewood SJ, Rozencweig S. La contention : un véritable défi Entretien avec Simon J. Littlewood. [ Retention : a challenging problem. An interview with Simon J. Littlewood]. Orthod Fr. 2020 Oct 01;91(3):173-178. doi: 10.1684/orthodfr.2020.18. French. PMID: 33146612.
Copy Download .nbib Format: NLM
The results of rapid source control laparotomy or open abdomen for acute diverticulitis.

Langenbeck's archives of surgery

Berg A, Rosenzweig M, Kuo YH, Onayemi A, Mohidul S, Moen M, Sciarretta J, Davis JM, Ahmed N.
PMID: 34455491
Langenbecks Arch Surg. 2021 Aug 28; doi: 10.1007/s00423-021-02304-8. Epub 2021 Aug 28.

INTRODUCTION: Rapid source control laparotomy (RSCL) for the management of non-traumatic intra-abdominal emergencies has increased over the past 25 years when it was advocated for trauma patients. Little data, however, support its widespread use. We hypothesize that the patients...

Cite
Berg A, Rosenzweig M, Kuo YH, et al. The results of rapid source control laparotomy or open abdomen for acute diverticulitis. Langenbecks Arch Surg. 2021;doi: 10.1007/s00423-021-02304-8.
Berg, A., Rosenzweig, M., Kuo, Y. H., Onayemi, A., Mohidul, S., Moen, M., Sciarretta, J., Davis, J. M., & Ahmed, N. (2021). The results of rapid source control laparotomy or open abdomen for acute diverticulitis. Langenbeck's archives of surgery, . https://doi.org/10.1007/s00423-021-02304-8
Berg, Arthur, et al. "The results of rapid source control laparotomy or open abdomen for acute diverticulitis." Langenbeck's archives of surgery vol. (2021). doi: https://doi.org/10.1007/s00423-021-02304-8
Berg A, Rosenzweig M, Kuo YH, Onayemi A, Mohidul S, Moen M, Sciarretta J, Davis JM, Ahmed N. The results of rapid source control laparotomy or open abdomen for acute diverticulitis. Langenbecks Arch Surg. 2021 Aug 28; doi: 10.1007/s00423-021-02304-8. Epub 2021 Aug 28. PMID: 34455491; PMCID: PMC8402969.
Copy Download .nbib Format: NLM
[The occlusal examination].

Revue odonto stomatologique du Nord-Est

Rosencweig D.
PMID: 4506301
Rev Odontostomatol Nordest. 1972;38-46.

No abstract available.

Cite
Rosencweig D. L'examen occlusal. [The occlusal examination]. Rev Odontostomatol Nordest. 1972;38-46
Rosencweig, D. (1972). L'examen occlusal. [The occlusal examination]. Revue odonto stomatologique du Nord-Est, 38-46.
Rosencweig, D. "L'examen occlusal." [The occlusal examination]. Revue odonto stomatologique du Nord-Est vol. (1972): 38-46.
Rosencweig D. L'examen occlusal. [The occlusal examination]. Rev Odontostomatol Nordest. 1972;38-46. French. PMID: 4506301.
Copy Download .nbib Format: NLM
Interventionist training and intervention fidelity monitoring and maintenance for CONNECT, a nurse-led primary palliative care in oncology trial.

Contemporary clinical trials communications

Robbins-Welty GA, Mueser L, Mitchell C, Pope N, Arnold R, Park S, White D, Smith KJ, Reynolds C, Rosenzweig M, Bakitas M, Schenker Y.
PMID: 29696159
Contemp Clin Trials Commun. 2018 Mar 15;10:57-61. doi: 10.1016/j.conctc.2018.03.006. eCollection 2018 Jun.

CONTEXT: Intervention fidelity is a critical component of behavioral research that has received inadequate attention in palliative care studies. With increasing focus on the need for palliative care models that can be widely disseminated and delivered by non-specialists, rigorous...

Cite
Robbins-Welty GA, Mueser L, Mitchell C, et al. Interventionist training and intervention fidelity monitoring and maintenance for CONNECT, a nurse-led primary palliative care in oncology trial. Contemp Clin Trials Commun. 2018;10:57-61doi: 10.1016/j.conctc.2018.03.006.
Robbins-Welty, G. A., Mueser, L., Mitchell, C., Pope, N., Arnold, R., Park, S., White, D., Smith, K. J., Reynolds, C., Rosenzweig, M., Bakitas, M., & Schenker, Y. (2018). Interventionist training and intervention fidelity monitoring and maintenance for CONNECT, a nurse-led primary palliative care in oncology trial. Contemporary clinical trials communications, 1057-61. https://doi.org/10.1016/j.conctc.2018.03.006
Robbins-Welty, Gregg A, et al. "Interventionist training and intervention fidelity monitoring and maintenance for CONNECT, a nurse-led primary palliative care in oncology trial." Contemporary clinical trials communications vol. 10 (2018): 57-61. doi: https://doi.org/10.1016/j.conctc.2018.03.006
Robbins-Welty GA, Mueser L, Mitchell C, Pope N, Arnold R, Park S, White D, Smith KJ, Reynolds C, Rosenzweig M, Bakitas M, Schenker Y. Interventionist training and intervention fidelity monitoring and maintenance for CONNECT, a nurse-led primary palliative care in oncology trial. Contemp Clin Trials Commun. 2018 Mar 15;10:57-61. doi: 10.1016/j.conctc.2018.03.006. eCollection 2018 Jun. PMID: 29696159; PMCID: PMC5898502.
Copy Download .nbib Format: NLM
[In Process Citation].

L' Orthodontie francaise

Rozencweig S.
PMID: 22717110
Orthod Fr. 2012 Jun;83(2):95-6. doi: 10.1051/orthodfr/2012014. Epub 2012 Jun 21.

No abstract available.

Cite
Rozencweig S. Avant-propos. [In Process Citation]. Orthod Fr. 2012;83(2):95-6doi: 10.1051/orthodfr/2012014.
Rozencweig, S. (2012). Avant-propos. [In Process Citation]. L' Orthodontie francaise, 83(2), 95-6. https://doi.org/10.1051/orthodfr/2012014
Rozencweig, Sophie. "Avant-propos." [In Process Citation]. L' Orthodontie francaise vol. 83,2 (2012): 95-6. doi: https://doi.org/10.1051/orthodfr/2012014
Rozencweig S. Avant-propos. [In Process Citation]. Orthod Fr. 2012 Jun;83(2):95-6. doi: 10.1051/orthodfr/2012014. Epub 2012 Jun 21. French. PMID: 22717110.
Copy Download .nbib Format: NLM
[In Process Citation].

L' Orthodontie francaise

Rozencweig G.
PMID: 23531297
Orthod Fr. 2013 Mar;84(1):145-6. doi: 10.1051/orthodfr/2013045. Epub 2013 Mar 27.

No abstract available.

Cite
Rozencweig G. J'ai lu pour vous. [In Process Citation]. Orthod Fr. 2013;84(1):145-6doi: 10.1051/orthodfr/2013045.
Rozencweig, G. (2013). J'ai lu pour vous. [In Process Citation]. L' Orthodontie francaise, 84(1), 145-6. https://doi.org/10.1051/orthodfr/2013045
Rozencweig, Georges. "J'ai lu pour vous." [In Process Citation]. L' Orthodontie francaise vol. 84,1 (2013): 145-6. doi: https://doi.org/10.1051/orthodfr/2013045
Rozencweig G. J'ai lu pour vous. [In Process Citation]. Orthod Fr. 2013 Mar;84(1):145-6. doi: 10.1051/orthodfr/2013045. Epub 2013 Mar 27. French. PMID: 23531297.
Copy Download .nbib Format: NLM
Letters to the editor.

Science (New York, N.Y.)

Rosenzweig M.
PMID: 17782007
Science. 1974 Oct 18;186(4160):198. doi: 10.1126/science.186.4160.198.

No abstract available.

Cite
Rosenzweig M. Letters to the editor. Science. 1974;186(4160):198doi: 10.1126/science.186.4160.198.
Rosenzweig, M. (1974). Letters to the editor. Science (New York, N.Y.), 186(4160), 198. https://doi.org/10.1126/science.186.4160.198
Rosenzweig, M. "Letters to the editor." Science (New York, N.Y.) vol. 186,4160 (1974): 198. doi: https://doi.org/10.1126/science.186.4160.198
Rosenzweig M. Letters to the editor. Science. 1974 Oct 18;186(4160):198. doi: 10.1126/science.186.4160.198. PMID: 17782007.
Copy Download .nbib Format: NLM
Management of Cancer Related Distress in Patients with a Hematological Malignancy.

Journal of hospice and palliative nursing : JHPN : the official journal of the Hospice and Palliative Nurses Association

Albrecht TA, Rosenzweig M.
PMID: 23002383
J Hosp Palliat Nurs. 2012 Oct 01;14(7):462-468. doi: 10.1097/NJH.0b013e318268d04e.

Patients with hematologic malignancies often require urgent, aggressive, and lengthy chemotherapy treatment. These treatment regimens, divided into cycles, result in extended, often isolating periods of hospitalization where any direct clinical benefit for the patient, such as remission or "no...

Cite
Albrecht TA, Rosenzweig M. Management of Cancer Related Distress in Patients with a Hematological Malignancy. J Hosp Palliat Nurs. 2012;14(7):462-468doi: 10.1097/NJH.0b013e318268d04e.
Albrecht, T. A., & Rosenzweig, M. (2012). Management of Cancer Related Distress in Patients with a Hematological Malignancy. Journal of hospice and palliative nursing : JHPN : the official journal of the Hospice and Palliative Nurses Association, 14(7), 462-468. https://doi.org/10.1097/NJH.0b013e318268d04e
Albrecht, Tara A, and Rosenzweig, Margaret. "Management of Cancer Related Distress in Patients with a Hematological Malignancy." Journal of hospice and palliative nursing : JHPN : the official journal of the Hospice and Palliative Nurses Association vol. 14,7 (2012): 462-468. doi: https://doi.org/10.1097/NJH.0b013e318268d04e
Albrecht TA, Rosenzweig M. Management of Cancer Related Distress in Patients with a Hematological Malignancy. J Hosp Palliat Nurs. 2012 Oct 01;14(7):462-468. doi: 10.1097/NJH.0b013e318268d04e. PMID: 23002383; PMCID: PMC3445415.
Copy Download .nbib Format: NLM
Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.

JCO precision oncology

Lee JK, Madison R, Classon A, Gjoerup O, Rosenzweig M, Frampton GM, Alexander BM, Oxnard GR, Venstrom JM, Awad MM, Schrock AB.
PMID: 34476332
JCO Precis Oncol. 2021 Aug 25;5. doi: 10.1200/PO.21.00122. eCollection 2021.

METHODS: Hybrid capture-based comprehensive genomic profiling (CGP) was performed on samples from 69,219 patients with NSCLC. For treatment patterns and outcomes analysis, patients with advanced RESULTS: A total of 1,592 patients with NSCLC (2.3%) were identified with 1,599 CONCLUSION:...

Cite
Lee JK, Madison R, Classon A, et al. Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns. JCO Precis Oncol. 2021;5doi: 10.1200/PO.21.00122.
Lee, J. K., Madison, R., Classon, A., Gjoerup, O., Rosenzweig, M., Frampton, G. M., Alexander, B. M., Oxnard, G. R., Venstrom, J. M., Awad, M. M., & Schrock, A. B. (2021). Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns. JCO precision oncology, 5. https://doi.org/10.1200/PO.21.00122
Lee, Jessica K, et al. "Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns." JCO precision oncology vol. 5 (2021). doi: https://doi.org/10.1200/PO.21.00122
Lee JK, Madison R, Classon A, Gjoerup O, Rosenzweig M, Frampton GM, Alexander BM, Oxnard GR, Venstrom JM, Awad MM, Schrock AB. Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns. JCO Precis Oncol. 2021 Aug 25;5. doi: 10.1200/PO.21.00122. eCollection 2021. PMID: 34476332; PMCID: PMC8407654.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 39 entries